drugset / Trial / NCT00272662
Study of Subcutaneously Administered Peginesatide in Anemic Cancer Patients Receiving Chemotherapy
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple subcutaneously administered injections of peginesatide in anemic cancer participants receiving chemotherapy.
Timeline
- Start
- 2006-01
- Primary completion
- 2007-06
- Completion
- 2007-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | peginesatide | Peptide | 0.05 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.1 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.15 mg/kg | Subcutaneous |
| Subject | peginesatide | Peptide | 0.2 mg/kg | Subcutaneous |